Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole

References

• ANDERSSON, T., HOLMBERG, J., Rifniss, K. and WALAN, A., 1998, Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. British Journal of Clinical Pharmacology, 45, 369–375.
   PubMed Web of Science ®Google Scholar
• ARONOFF, G. R., BERGSTROM, R. F., BOPP, R. J., SLOAN, R. S. and CALLAGHAN, J. T., 1988, Nizatidine disposition in subjects with normal and impaired renal function. Clinical Pharmacology and Therapeutics, 43, 688–695.
   PubMed Web of Science ®Google Scholar
• BEDFORD, T. A. and ROWBOTHAM, D. J., 1996, Cisapride drug interaction of clinical significance. Drug Safety, 15, 167–175.
   PubMed Web of Science ®Google Scholar
• DIXON, M., 1953, The determination of enzyme inhibitor constants. Biochemical journal, 55, 170–171.
   PubMed Web of Science ®Google Scholar
• FURUTA, T., OHASHI, K., KOBAYASHI, K., ImA, I., YOSHIDA, H., SHIRAI, N., TAKASHIMA, M., KOSUGE, K., HANAI, H., CHIBA, K., ISHIZAKI, T. and KANEKO, E., 1999, Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clinical Pharmacology and Therapeutics, 66, 265–274.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., MARTIN, M. V., BEAUNE, P. H., KREMERS, P., WOLFF, T. and WAXMAN, D. J., 1986, Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 261, 5051–5060.
   PubMed Web of Science ®Google Scholar
• HUMPHRIES, T. J., 1991, Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Digestive Diseases and Sciences, 36, 1665–1669.
   PubMed Web of Science ®Google Scholar
• ISHIZAKI, T., CHIBA, K., MANABE, K., KOYAMA, E., HAYASHI, M., YASUDA, S., HORAI, Y., TOMONO, Y., YAMATO, C. and TOYOKI, T., 1995, Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Clinical Pharmacology and Therapeutics, 58, 155–164.
   PubMed Web of Science ®Google Scholar
• KARAM, W. G., GOLDSTEIN, J. A., LASKER, J. M. and GHANAYEM, B. I., 1996, Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metabolism and Disposition, 24, 1081-1 087.
   Google Scholar
• KATASHIMA, M., YAMAMOTO, K., TOKUMA, Y., HATA, T., SAWADA, Y. and IGA, T., 1998, Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. European Journal of Drug Metabolism and Pharmacokinetics, 23, 19–26.
   PubMed Web of Science ®Google Scholar
• KATOH, M., NAKAJIMA, M., SHIMADA N., YAMAZAKI H. and YOKOI, T., 2000, Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. European Journal of Clinical Pharmacology, 55, 843–852.
   Google Scholar
• KLOTZ, U., 1987, Lack of effect of nizatidine on drug metabolism. Scandinavian Journal of Gastroenterology, 22, 18–23.
   Web of Science ®Google Scholar
• KNODELL, R. G., BROWNE, D. G., GWOZDZ, G. P., BRIAN, W. R. and GUENGERICH, F. P., 1991, Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastro-enterology, 101, 1680–1691.
   PubMed Web of Science ®Google Scholar
• Ko, J.-W., SUKHOVA, N., THACKER, D., CHEN, P. and FLOCKHART, D. A., 1997, Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition, 25, 853–862.
   Google Scholar
• KOBAYASHI, H. and KOBAYASHI, S., 1999, Enantiomer-enantiomer interaction of a calcium channel antagonist, benidipine hydrochloride, during liver metabolism in the rat. European Journal of Drug Metabolism and Pharmacokinetics, 24, 121-12 6.
   Google Scholar
• LEEMANN, T., TRANSON, C. and DAYER, P., 1993, Cytochrome P45 OTB (CYP2C): a major mono-oxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sciences, 52, 29–34.
   PubMed Web of Science ®Google Scholar
• LIN, J. H., 1991, Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists: relationship between intrinsic potency and effective plasma concentrations. Clinical Pharmacokinetics, 20, 218–236.
   PubMed Web of Science ®Google Scholar
• MiicK, W., HEINE, P. R., BREUEL, H. P., NIKLAUS, H., HORKULAK, J. and AHR, G., 1995, The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics, 33, 89–94.
   PubMed Web of Science ®Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. Journal of Biological Chemistry, 239, 2370-2 378.
   Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s : evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotka, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• PARKER, A. C., PRITCHARD, P., PRESTON, T., DALZELL, A. M. and CHOONARA, I., 1997, Lack of inhibitory effect of cimetidine on caffeine metabolism in children using the caffeine breath test. British Journal of Clinical Pharmacology, 43, 467–470.
   PubMed Web of Science ®Google Scholar
• PASANEN, M., ARVELA, P., PELKONEN, 0., SOTANIEMI, E. and KLOTZ, U., 1986, Effect of five structurally diverse H2-receptor antagonists on drug metabolism. Biochemical Pharmacology, 35, 4457–4461.
   Google Scholar
• PELKONEN, 0., MAENPVA, J., TAAVITSAINEN, P., RAUTIO, A. and RAUNIO, H., 1998, Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotka, 28, 1203–1253.
   Google Scholar
• PRUEKSARITANONT, T., GORHAM, L. M., MA, B., Liu, L., Yu, X., ZHAO, J. J., SLAUGHTER, D. E., ARISON, B. H. and VYAS, K. P., 1997, In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P45 Os. Drug Metabolism and Disposition, 25, 1191–1199.
   PubMed Web of Science ®Google Scholar
• RIEUTORD, A., STUPANS, I., SHENFIELD, G. M. and GROSS, A. S., 1995, Gliclazide hydroxylation by rat liver microsomes. Xenobiotica, 25, 1345–1354.
   PubMed Web of Science ®Google Scholar
• RING, B. J., BINKLEY, S. N., VANDENBRANDEN, M. and WRIGHTON, S. A., 1996, In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. British Journal of Clinical Pharmacology, 41, 181–186.
   PubMed Web of Science ®Google Scholar
• SOHN, D.-R., KOBAYASHI, K., CHIBA, K., LEE, K.-H., SHIN, S.-G. and ISHIZAKI, T., 1992, Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an oriental population. Journal of Pharmacology and Experimental Therapeutics, 262, 1195–1202.
   PubMed Web of Science ®Google Scholar
• TOON, S., HOLT, B. L., MULLINS, F. G. P. and KHAN, A., 1995, Effects of cimetidine, ranitidine and omeprazole on tolbutamide pharmacokinetics. Journal of Pharmacy and Pharmacology, 47,85–88.
   Google Scholar
• WRIGHTON, S. A. and RING, B. J., 1994, Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharmaceutical Research, 11, 921–924.
   PubMed Web of Science ®Google Scholar
• ZECH, K., STEINIJANS, V. W., HUBER, R., KOLASSA, N. and RADTKE, H. W., 1996, Pharmacokinetics and drug interactions-relevant factors for the choice of a drug. International Journal of Clinical Pharmacology and Therapeutics, 34, S3–6.
   Web of Science ®Google Scholar